poisar

Stock

Kamada Ltd. KMDA

$7.57+4.20%

Overview

KMDA market data

Price History

KMDA price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
20.25
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.35
Diluted earnings per share over the trailing twelve months.
Beta
0.89
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
3.6%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
11.2%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$6.50 – $9.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $412.5M · P/B 1.51 · P/S 2.27.

Company News

7 captured
Kamada Announces CFO Chaime Orlev To Depart Effective December 31 To Pursue Other Opportunities; Successor Search UnderwayBenzinga · Aug 12, 2026, 11:08 AM
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M EstBenzinga · Aug 12, 2026, 11:07 AM
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M EstimateBenzinga · Aug 12, 2026, 11:07 AM
Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026Benzinga · Jul 20, 2026, 11:07 AM
Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ TransplantationBenzinga · Jul 13, 2026, 11:19 AM
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing LaboratoryGlobenewswire Inc · Jun 1, 2026, 11:15 AM
Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test LaboratoryBenzinga · Jun 1, 2026, 11:05 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock